Frontlight ResearchEarly access
CompletedPhase 1
A study to test a single administration of three dose levels of ATX101 in healthy adults.
Key facts
- Who runs it
- Aurobac Therapeutics S.A.S.
- Where
- Portugal1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 24 people enrolled
- Started
- 16 Jul 2025
- Ended
- 24 Oct 2025
- Type of study
- Interventional
- Record updated
- 10 October 2025
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Where is this trial?
It has sites in one country. Choose a country to see its sites.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 10 October 2025